Daily non-political popular news in brief.

Bevacizumab found to improve survival for patients with advanced breast cancer

12-26-2007 · EurekAlert!

Inhibiting the growth of blood vessels that supply tumors slows the progression of metastatic breast cancer according to results of a large clinical trial of Avastin, an antiangiogenic therapy. The study, published in the Dec. 27 issue of the New England Journal of Medicine, found that Avastin in combination with chemotherapy significantly prolongs progression-free survival for women with breast cancer compared to chemotherapy alone.

Keywords: bevacizumab, improve, survival, patients, advanced, breast, cancer, patient

« Previous | Next »

Similar news on "Bevacizumab found to improve survival for patients with advanced breast cancer":

New biomarker predicts effectiveness of breast cancer drugs
12-07-2006 · EurekAlert!
University of Cincinnati researchers have identified a new way to predict when anti-estrogen drug therapies are inappropriate for patients with hormone-dependent breast cancer.Scientists say these findings could help physicians more accurately predict which tumors will respond to anti-estrogen therapy and improve long-term survival for breast cancer patients.
Similar news · Read more »
Personalized diets may offer relief to advanced cancer patients
03-09-2007 · EurekAlert!
Researchers at the University of Alberta studying the effects of chemotherapy and radiation therapy on the senses report that most advanced cancer patients experience unique and persistent taste and smell abnormalities, believed to be a key factor in malnutrition and poor quality of life. Their study suggests that every patient with chemosensory dysfunction has unique symptoms, and a diet tailored to his/her needs would likely improve quality of life.
Similar news · Read more »
Gene patenting -- steep cost for health care and patients
05-07-2007 · EurekAlert!
The drug trastuzumab (Herceptin) is used to treat HER2-positive breast cancer (a type of breast cancer that overexpresses the HER2 gene and accounts for about 25 percent of all breast cancers). Trastuzumab therapy improves the chances of survival; however, it has deleterious side effects and is expensive. Thus, it is important to accurately determine the patient's HER2 status.
Similar news · Read more »
Group therapy fails to improve breast cancer survival
07-23-2007 · EurekAlert!
A follow up to a previous study on group therapy in breast cancer patients finds group therapy does not prolong the lives of women with metastatic breast cancer.
Similar news · Read more »
Combining therapies can improve survival for early-stage breast cancer patients
04-03-2007 · EurekAlert!
Patients with early-stage breast cancer who are treated with both chemotherapy and tamoxifen have a higher survival rate than patients who receive only tamoxifen. But a combination of tamoxifen and ovarian suppression -- treatment to stop the ovaries from functioning -- did not show any additional benefits, according to two randomized clinical trials published in the April 4 Journal of the National Cancer Institute.
Similar news · Read more »
Oncologists are critical in managing psychiatric disorders in patients with advanced cancer
09-10-2007 · EurekAlert!
Mental illness and emotional distress in patients with advanced cancer are often overlooked by oncologists but, if screened for, can be adequately managed to improve a patient's quality of life.
Similar news · Read more »
Anthracyclines improve survival in HER2-positive breast cancer patients
12-25-2007 · EurekAlert!
Treatment with the class of chemotherapy drugs called anthracyclines improves survival in women with HER2-positive breast cancer who have previously had surgery, but it may not offer any benefit for women with HER2-negative tumors, according to a study published online Dec. 25 in the Journal of the National Cancer Institute.
Similar news · Read more »
Jefferson scientists show gene reverts cancer genes to normal, predicts breast cancer prognosis
10-31-2006 · EurekAlert!
Scientists have shown that the activity of a gene that commandeers other cancer-causing genes, returning them to normal, can predict the prognosis of an individual with breast cancer. They looked at cancer cells from more than 2,000 breast cancer patients and found that this commandeering or "organizing" ability is increasingly lost in cancer cells and associated with the progression of disease. The more the gene is expressed in breast cancer, the better the patient did.
Similar news · Read more »
Breast cancer survival rates improved by novel drug sequence, say researchers
02-12-2007 · EurekAlert!
Changing the way women are treated for breast cancer could improve their overall chance of survival, according to research published today in the Lancet. The new paper shows that switching to a drug called exemestane, two to three years after commencing standard therapy with the drug tamoxifen, can cut the risk of death for certain women by a further 17 percent compared with using tamoxifen alone.
Similar news · Read more »
Other highlights in the May 2 JNCI
05-01-2007 · EurekAlert!
Also in the May 2 JNCI is a follow-up to the Italian Randomized Tamoxifen Trial, a study on treating breast cancer patients with three HER inhibitor drugs, an increase in survival rates for indolent lymphoma patients using a chemotherapy-rituximab combination, and new lung cancer risk prediction models.
Similar news · Read more »